Influence of Opioid Agonists on Cardiac Human Ether-a-go-go-related Gene K+ Currents
- 1 January 2002
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 303 (2) , 688-694
- https://doi.org/10.1124/jpet.102.038240
Abstract
We have evaluated the ability of various opioid agonists, including methadone, l-α-acetylmethadol (LAAM), fentanyl, meperidine, codeine, morphine, and buprenorphine, to block the cardiac human ether-a-go-go-related gene (HERG) K+current (IHERG) in human cells stably transfected with the HERG potassium channel gene. Our results show that LAAM, methadone, fentanyl, and buprenorphine were effective inhibitors of IHERG, with IC50 values in the 1 to 10 μM range. The other drugs tested were far less potent with respect to IHERG inhibition. Compared with the reported maximal plasma concentration (Cmax) after administration of therapeutic doses of these drugs, the ratio of IC50/Cmax was highest for codeine and morphine (>455 and >400, respectively), thereby indicating that these drugs have the widest margin of safety (of the compounds tested) with respect to blockade of IHERG. In contrast, the lowest ratios of IC50/Cmax were observed for LAAM and methadone (2.2 and 2.7, respectively). Further investigation showed that methadone block of IHERG was rapid, with steady-state inhibition achieved within 1 s when applied at its IC50 concentration (10 μM) for IHERG block. Results from “envelope of tails” tests suggest that the majority of block occurred when the channels were in the open and/or inactivated states, although ∼10% of the available HERG K+ channels were apparently blocked in a closed state. Similar results were obtained for LAAM. These results demonstrate that LAAM and methadone can block IHERG in transfected cells at clinically relevant concentrations, thereby providing a plausible mechanism for the adverse cardiac effects observed in some patients receiving LAAM or methadone.This publication has 38 references indexed in Scilit:
- Methadone Use in Cancer Patients with Pain: A ReviewJournal of Palliative Medicine, 2002
- Torsades de PointesAssociated with High Dose Levomethadyl Acetate (ORLAAM®)Journal of Addictive Diseases, 2001
- Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmiasExpert Opinion on Pharmacotherapy, 2000
- Cellular and Ionic Mechanisms Underlying Erythromycin-Induced Long QT Intervals and Torsade de PointesJournal of the American College of Cardiology, 1996
- Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer painJournal of Pain and Symptom Management, 1996
- Pharmacokinetics of methadone and its primary metabolite in 20 opiate addictsEuropean Journal of Clinical Pharmacology, 1995
- Drug-Induced Torsade de PointesDrug Safety, 1994
- Human Pharmacokinetic Study of Immediate-Release (Codeine Phosphate) and Sustained-Release (Codeine Contin) CodeineThe Journal of Clinical Pharmacology, 1994
- SHARP FALL IN BLOOD PRESSURE AFTER INJECTION OF HEPARIN CONTAINING CHLORBUTOLThe Lancet, 1986
- Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patchesPflügers Archiv - European Journal of Physiology, 1981